DGAP-News: Epigenomics AG / Key word(s): Miscellaneous 2016-05-02 / 08:00 The issuer is solely responsible for the content of this announcement. Press release China FDA names Epigenomics’ blood-based Septin9 colorectal cancer test a most innovative medical product for 2015 – Only 9 out of 7530 approved medical devices in 2015 were named “innovative medical product” […]
Category: Press Releases
02. May 2016
Epigenomics AG: China FDA names Epigenomics’ blood-based Septin9 colorectal cancer test a most innovative medical product for 2015
Read more
27. April 2016
Epigenomics announces commercial launch of Epi proColon(R) in the U.S.
DGAP-News: Epigenomics AG / Key word(s): Product Launch 2016-04-27 / 07:49 The issuer is solely responsible for the content of this announcement. Press release Epigenomics announces commercial launch of Epi proColon(R) in the U.S. Berlin (Germany) and Germantown, MD (U.S.A.), April 26, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer […]
18. April 2016
Epigenomics AG: Epigenomics to present data on novel blood-based test for the detection of lung cancer at AACR Annual Meeting 2016
DGAP-News: Epigenomics AG / Key word(s): Conference/Scientific publication 2016-04-18 / 11:15 The issuer is solely responsible for the content of this announcement. Epigenomics to present data on novel blood-based test for the detection of lung cancer at AACR Annual Meeting 2016 Berlin (Germany) and Germantown, MD (U.S.A.), April 18, 2016 – Epigenomics AG (Frankfurt Prime […]
30. March 2016
Epigenomics AG: Epigenomics enters strategic license and development agreement with BioChain on novel, blood-based lung cancer test
DGAP-News: Epigenomics AG / Key word(s): Alliance/Miscellaneous 2016-03-30 / 09:10 The issuer is solely responsible for the content of this announcement. Epigenomics enters strategic license and development agreement with BioChain on novel, blood-based lung cancer test BioChain to acquire exclusive development and commercial license for China Initiation of clinical study planned in 2016 with the […]
18. March 2016
Epigenomics AG Reports Results for the Financial Year Ended December 31, 2015 and Provides Outlook for 2016
DGAP-News: Epigenomics AG / Key word(s): Final Results/Forecast 2016-03-18 / 06:00 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG Reports Results for the Financial Year Ended December 31, 2015 and Provides Outlook for 2016 – Product revenue growth of 88% year-on-year driven by successful start of commercialization of […]
18. December 2015
Epigenomics AG: Bondholders resolve on amendment of the terms and conditions of the 2013 Convertible Bonds
DGAP-News: Epigenomics AG / Key word(s): Bond 2015-12-18 / 17:23 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG: Bondholders resolve on amendment of the terms and conditions of the 2013 Convertible Bonds: – Extension of the Term until December 31, 2016 – Amendment of the Anti-Dilution Protection Berlin […]